Contains fulltext :
                  87321.pdf (publisher's version ) (Open Access

A Barden

A Brennan

Anonymus

B Sibai

C Osmond

CA Meads

Carmen D Dirksen

CD Spielberger

CM Koopmans

Denise HJ Delahaije

DJ Barker

EB Foa

Hein W Bruinse

J Williams

J Zhang

JB Oostenbrink

JC van Houwelingen

JG Eriksson

Jim van Eyck

JK Erbaugy

JM Davison

JM Schutte

Johannes J Duvekot

Joris AM van der Post

K Haram

Laura D de Wit-Zuurendonk

Louis L Peeters

Luc J Smits

MA Brown

Marc E Spaanderman

Mariëlle G van Pampus

Mark ABHM van der Hoeven

MJ Buxton

NVOG

PRN/TNO

R Berkow

RB D'Agostino

S Sep

Sander MJ van Kuijk

Simone JS Sep

SJS Sep

Société française d'anesthésie et de réanimation (Sfar), Collège national des gynécologues et obstétriciens français (CNGOF), Société française de médecine périnatale (SFMP) and Société française de néonatalogie (SFNN)

BMC Pregnancy and Childbirth

English

PubMed

Crossref

Cost-effectiveness of recurrence risk guided care versus care as usual in women who suffered from early-onset preeclampsia including HELLP syndrome in their previous pregnancy (the PreCare study)

Springer - Publisher Connector

Delahaije, D.H.

Kuijk, S.M. van

Dirksen, C.D.

Sep, S.J.

Peeters, L.L.

Spaanderman, M.E.A.

Bruinse, H.W.

Wit-Zuurendonk, L.D. de

Post, J.A. van der

Duvekot, J.J.

Eyck, J. van

Pampus, M.G. van

Hoeven, M.A. van der

Smits, L.J.

Radboud Repository

Cost-effectiveness of recurrence risk guided care versus care as usual in women who suffered from early-onset preeclampsia including HELLP syndrome in their previous pregnancy (the PreCare study).

Background: Preeclampsia and HELLP syndrome may have serious consequences for both mother and fetus. Women who have suffered from preeclampsia or the HELLP syndrome, have an increased risk of developing preeclampsia in a subsequent pregnancy. However, most women will develop no or only minor complications. In this study, we intend to determine cost-effectiveness of recurrence risk guided care versus care as usual in pregnant women with a history of early-onset preeclampsia.Methods/design: We developed a prediction model to estimate the individual risk of recurrence of early-onset preeclampsia and the HELLP syndrome. In a before-after study, pregnant women with preeclampsia or HELLP syndrome in their previous pregnancy receiving care as usual (before introduction of the prediction model) will be compared with women receiving recurrence risk guided care (after introduction of the prediction model).Eligible and pregnant women will be recruited at six university hospitals and seven large non-university tertiary referral hospitals in the Netherlands.The primary outcome measure is the recurrence of early-onset preeclampsia or HELLP syndrome in women allocated to the regular monitoring group.For the economic evaluation, a modelling approach will be used. Costs and effects of recurrence risk guided care with those of care as usual will be compared by means of a decision model. Two incremental cost-effectiveness ratios will be calculated: 1) cost per Quality Adjusted Life Year (mother unit of analysis) and 2) cost per live born child (child unit of analysis).Discussion: This is, to our knowledge, the first study that evaluates prospectively the efficacy of a multivariable prediction rule for recurrent hypertensive disease in pregnancy. Results of this study could either be integrated into the current guideline on Hypertensive Disorders in Pregnancy, or be used to develop a new guideline

Delahaije, D.H.J. (Denise)

Kuijk, S.M.J. (Sander) van

Dirksen, C.D. (Carmen)

Sep, S.J.S. (Simone)

Peeters, L.L. (Louis)

Bruinse, H.W. (Hein)

Wit-Zuurendonk, L.D. (Laura) de

Post, J.A.M. (Joris) van der

Duvekot, J.J. (Hans)

Eyck, J. (Jim) van

Pampus, M.G. (Mariëlle) van

Hoeven, M.A.B.H.M. (Mark) van der

Smits, L.J. (Luc)

Erasmus University Digital Repository

ABSTRACT: BACKGROUND: Preeclampsia and HELLP syndrome may have serious consequences for both mother and fetus. Women who have suffered from preeclampsia or the HELLP syndrome, have an increased risk of developing preeclampsia in a subsequent pregnancy. However, most women will develop no or only minor complications. In this study, we intend to determine cost-effectiveness of recurrence risk guided care versus care as usual in pregnant women with a history of early-onset preeclampsia. METHODS/DESIGN: We developed a prediction model to estimate the individual risk of recurrence of early-onset preeclampsia and the HELLP syndrome. In a before-after study, pregnant women with preeclampsia or HELLP syndrome in their previous pregnancy receiving care as usual (before introduction of the prediction model) will be compared with women receiving recurrence risk guided care (after introduction of the prediction model).Eligible and pregnant women will be recruited at six university hospitals and seven large non-university tertiary referral hospitals in the Netherlands.The primary outcome measure is the recurrence of early-onset preeclampsia or HELLP syndrome in women allocated to the regular monitoring group.For the economic evaluation, a modelling approach will be used. Costs and effects of recurrence risk guided care with those of care as usual will be compared by means of a decision model. Two incremental cost-effectiveness ratios will be calculated: 1) cost per Quality Adjusted Life Year (mother unit of analysis) and 2) cost per live born child (child unit of analysis). DISCUSSION: This is, to our knowledge, the first study that evaluates prospectively the efficacy of a multivariable prediction rule for recurrent hypertensive disease in pregnancy. Results of this study could either be integrated into the current guideline on Hypertensive Disorders in Pregnancy, or be used to develop a new guideline

van Kuijk, S.M.

Spaanderman, M.E.

de Wit-Zuurendonk, L.D.

van der Post, J.A.

van Eyck, J.

van Pampus, M.G.

van der Hoeven, M.A.

University of Groningen Digital Archive

NARCIS 

ABSTRACT: BACKGROUND: Preeclampsia and HELLP syndrome may have serious consequences for both mother and fetus. Women who have suffered from preeclampsia or the HELLP syndrome, have an increased risk of developing preeclampsia in a subsequent pregnancy. However, most women will develop no or only minor complications. In this study, we intend to determine cost-effectiveness of recurrence risk guided care versus care as usual in pregnant women with a history of early-onset preeclampsia. Methods/design: We developed a prediction model to estimate the individual risk of recurrence of early-onset preeclampsia and the HELLP syndrome. In a before-after study, pregnant women with preeclampsia or HELLP syndrome in their previous pregnancy receiving care as usual (before introduction of the prediction model) will be compared with women receiving recurrence risk guided care (after introduction of the prediction model). Eligible and pregnant women will be recruited at six university hospitals and seven large non-university tertiary referral hospitals in the Netherlands. The primary outcome measure is the recurrence of early-onset preeclampsia or HELLP syndrome in women allocated to the regular monitoring group. For the economic evaluation, a modelling approach will be used. Costs and effects of recurrence risk guided care with those of care as usual will be compared by means of a decision model. Two incremental cost-effectiveness ratios will be calculated: 1) cost per Quality Adjusted Life Year (mother unit of analysis) and 2) cost per live born child (child unit of analysis). DISCUSSION: This is, to our knowledge, the first study that evaluates prospectively the efficacy of a multivariable prediction rule for recurrent hypertensive disease in pregnancy. Results of this study could either be integrated into the current guideline on Hypertensive Disorders in Pregnancy, or be used to develop a new guidelin

Delahaije, Denise H. J.

van Kuijk, Sander M. J.

Dirksen, Carmen D.

Sep, Simone J. S.

Peeters, Louis L.

Spaanderman, Marc E.

Bruinse, Hein W.

de Wit, Laura D.

van der Post, Joris A. M.

Duvekot, Johannes J.

van Eyck, Jim

van Pampus, Marielle G.

van der Hoeven, Mark A. H. B. M.

Smits, Luc J.

6 - Hypertensieve aandoeningen in de zwangerschap, versie 2.0; mei

Abildgaard U: The HELLP syndrome: Clinical issues and management. A Review. BMC Pregnancy Childbirth

Akehurst R: Modelling in Health Economic Evaluation: What is its place? What is its value? Pharmacoeconomics

Anonymus: EuroQoL–a new facility for the measurement of healthrelated quality of life. The EuroQol Group. Health Policy

C: Critical care in obstetrics: pregnancy-specific conditions. Best Pract Res Clin Obstet Gynaecol

CH: An inventory for measuring depression. Arch Gen Psychiatry

Construction, validation and updating of a prognostic model for kidney graft survival. Stat Med

Early growth and coronary heart disease in later life: longitudinal study. BMJ

Fall CH: Growth in utero and serum cholesterol concentrations in adult life. BMJ

FC: New aspects in the pathophysiology of preeclampsia.

FFH: Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Amstelveen: College voor Zorgverzekeringen (CVZ)

Fletscher AJ: Merck Manual Medisch handboek Bohn Stafleu Van Loghum,

Infant growth and stroke in adult life: the Helsinke Birth Cohort Study. Stroke

JC: Validation, calibration, revision and combination of prognostic survival models. Stat Med

KS: Methods of prediction and prevention of preeclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess

Lancet

LLH: Simple prepregnant prediction rule for recurrent early-onset hypertensive disease in pregnancy. Reprod Sci

Lushene RE: STAI Manual for the State- trait Anxiety Inventory. Consulting Psychologists Press:

Pampus MG: Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet

Pre-eclampsia: contribution of maternal constitutional factors and the consequences for cardiovascular health. Clin Exp Pharmacol Physiol

Prediction tests for recurrent hypertensive disease in pregnancy, a systematic review. Hypertens Pregnancy

RJ: Risks of hypertensive disorders in the second pregnancy. Paediatr Perinat Epidemiol

Society of Obstetricians and Gynaecologists of Canada: Diagnosis, evaluation and management of the hypertensive disorders of pregnancy.

Steegers EAP: Substandard care in maternal mortality due to hypertensive disease in pregnancy in the Netherlands. BJOG

The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy

thuisbevalling in Nederland, 1995-2002. Rapportage over de jaren 2001-2002 van PRN/TNO.

Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA

Vray M: Modelling in economic evaluation: an unavoidable fact of life. Health Econ

Cost-effectiveness of recurrence risk guided care versus care as usual in women who suffered from early-onset preeclampsia including HELLP syndrome in their previous pregnancy (the PreCare study)

Abstract

Similar works

Full text

Available Versions

Crossref

Springer - Publisher Connector

Radboud Repository

Erasmus University Digital Repository

University of Groningen Digital Archive

NARCIS

NARCIS